AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...
pharmaphorum3d
BMS wagers $14bn on Karuna’s schizophrenia drug
Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approximately $14 billion.
Seeking Alpha17d
Bristol Myers posts long-term Phase 3 data for schizophrenia drug Cobenfy
Bristol Myers Squibb (NYSE:BMY ... and efficacy of Cobenfy in 156 adults with schizophrenia who had previously received the drug as part of the company’s five-week EMERGENT-2 or EMERGENT ...
Newsday18d
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Some people who took a new schizophrenia drug for a year improved with only ... people lost a few pounds while taking Cobenfy, made by Bristol Myers Squibb. Dr. John Krystal of Yale University ...
Bristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide Moat
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
Nasdaq17d
Bristol-Myers Squibb’s (NYSE:BMY) Schizophrenia Drug Sees Positive Results
Shares of Bristol-Myers Squibb (BMY) are down today despite the drugmaker providing positive results for its schizophrenia therapy, COBENFY. The drug proved that it can provide long-lasting ...
AbbVie tumbles on drug test disappointment, Bristol-Myers gains
AbbVie (ABBV) shares slide after its schizophrenia drug failed to meet the goals of its mid-stage trial. Shares of ...
What's Going On With Bristol-Myers Squibb Shares Monday?
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...
The Associated Press on MSN18d
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Some people who took a new schizophrenia drug for a year improved with only a few side ... people lost a few pounds while ...